China Releases Comprehensively Revised Implementing Provisions of Drug Administration Law

The revised Implementing Provisions of the Drug Administration Law (“New Provisions”) published by the State Council took effect on 15 May 2026. The Implementing Provisions serve as the principal administrative regulation supporting the PRC Drug Administration Law. They represent the first comprehensive overhaul of the Implementing Provisions in twenty-three years since their original enactment, with over 90% of articles amended or revised. These New Provisions reinforce the Market Authorization Holder’s (“MAH”)’s primary responsibility and establishing rigorous supervision across the full lifecycle of a drug product.

1. Recognition of Overseas Research Data

Article 10 of the New Provisions provides that overseas research data meeting the requirements of the National Medical Products Administration (“NMPA”) may be used to support drug registration applications in China.  Note that the acceptance of overseas clinical trial data has been encouraged at the policy level since 2017, and technical guidance was issued by the NMPA in 2018, but without upper level legal provisions. The New Provisions now formalize this legal basis. The rule operates on a compliance-based principle: overseas data is acceptable only where it meets applicable Chinese laws, regulations, standards, and norms.

2. Fast Track Drug Approval Pathways

The New Provisions provides for four fast track approval pathways at the level of administrative regulation: (i) the breakthrough therapy approval procedure, (ii) the conditional approval procedure, (iii) the priority review and approval procedure, and (iv) the special approval procedure. 

Previously established only at the level of NMPA’s departmental rules under the 2020 Administration Measures on Drug Registration, the New Provisions give them a substantially stronger legal basis to expediting patient access to innovative and urgently needed drugs.

Each pathway targets a distinct category of need: 

• the breakthrough therapy approval procedure and priority review procedure are designed to accelerate the development and approval of drugs addressing serious or life-threatening conditions. 
• the conditional approval allows market authorization on the basis of early clinical data where unmet medical need is high, subject to post-approval obligations. 
• the special approval procedure is designed for drugs urgently required in response to public health emergencies. 

These pathways are expected to shorten approval timelines for innovative drug products and encourage earlier investment in research and development targeting unmet clinical needs in China.

3. Clinical Trial Data Protection and Market Exclusivity

The New Provisions strengthen intellectual property protection for drug innovators in China through the following two mechanism:

a) Data protection 

According to Article 22, the MAH’s undisclosed clinical trial data submitted in support of a drug registration application, covering drugs containing new chemical entities and other qualifying products, shall be protected for up to six years from the date of registration. During this period, third parties are not allowed to use that data to support their own registration applications or use it for any improper commercial exploitation without the MAH’s consent. 

While a version of this regime has already existed in principle since 2002 only for “drugs containing new chemical entities”, implementing rules were never formally enacted, which make it impossible to be implemented in practice. 

Note that the draft Implementation Measures for Drug Trial Data Protection and the draft Work Procedures for Drug Trial Data Protection were released in 2025 for public comments. If the above two Measures and Procedures are enacted, the New Provisions now give this regime clear guiding procedure for the first time. 

b) Market Exclusivity 

According to Article 21, qualified pediatric drugs (including new product, new dosage or new specification, expanded indication) are eligible for up to two years of market exclusivity, and qualified rare disease drugs are eligible for up to seven years, provided the MAH commits to ensuring supply. The specific eligibility conditions and procedures are to be further elaborated by the NMPA in subsequent regulations.

4. Segmented Contract Manufacturing Permitted under Administrative Regulation

Article 32 of the New Provisions provides for segmented contract manufacturing, i.e., a production model under which different stages of the manufacturing process are carried out by different contracted manufacturers, for a defined category of drug products. 

Eligible categories include: 

a) innovative drugs with specialized process or equipment requirements, 

b) drugs designated as clinically urgent by the relevant health authorities, drugs required for public health emergency response, and reserve drugs, and 

c) a residual catch-all category reserved for products designated by the NMPA.

In addition, where production capacity of a vaccine MAH is insufficient, the MAH may, with NMPA approval, commission a qualified vaccine manufacturer to produce or carry out the segmented contract manufacturing. The permitted scenarios include: (1) production of multivalent or combined vaccines; (2) relevant departments of the State Council propose an urgent need for disease prevention and control, or for stockpiling purposes; and (3) other circumstances as prescribed by the drug supervision and administration department under the State Council.

The provisions of segmented contract manufacturing are to formalize the pilot program of segmented contract manufacturing launched in October 2024, which was scheduled to run until the end of 2026.

The New Provisions clarify that the MAH is required to establish a unified quality assurance system covering the entire production process and all manufacturing sites, ensuring continuous compliance with statutory requirements throughout.

5. Third-Party Platform Liability in Online Drug Sales

The New Provisions provide for the responsibilities of third-party platforms operating in the online drug sales market. 

According to Article 45, platforms are now expressly required to establish a dedicated drug quality and safety management body, staff it with qualified pharmaceutical personnel, and implement a range of internal management systems covering drug information display, quality management, delivery management, etc. 

Platforms must also conduct qualification reviews of drug sellers seeking to list on their platforms and inspection of the displayed drug information and maintain the relevant records. However, please note that the Regulations on the Supervision and Administration of Online Drug Sales, issued in 2022, had already established a relatively comprehensive framework governing platform responsibility. The New Provisions formalize therefore the above provisions.

It is especially worthnoting that how platform liability is treated in the context of traffic redirection where a platform directs users to third-party pages for drug purchases. Under the New Provisions, platforms that facilitate such redirection in violation of regulatory requirements may be subject to administrative penalties ranging from a corrective order and confiscation of unlawful gains, a fine ranging from RMB 100,000 to RMB 2,000,000 depending on the severity of the violation. This reflects a broader regulatory intent to prevent platforms from using technical arrangements to distance themselves from legal responsibility for drug sales activity occurring on or through their infrastructure. Platform operators and their in-house counsel should review existing traffic management and merchant onboarding arrangements carefully in light of these requirements.

6. Conclusion

The New Provisions represent the most comprehensive overhaul of the Implementing Rules in over two decades. While quite a few substantive content is aimed at consolidating and formalizing the existing rules and practices that have developed since the introduction of the MAH regime, the revision also introduces new provisions, including clinical trial data protection, market exclusivity periods, etc., that are likely to have an impact on commercial and regulatory planning, particularly for innovative and rare disease drug developers. 

Businesses operating in China’s pharmaceutical sector should conduct an overall assessment of their existing compliance frameworks with regard to the New Provisions. It is also highly recommended that companies should also assess whether the new provisions, such as data protection, market exclusivity, etc., make affect or benefit their future market strategies, licensing arrangements, or M&A transactions in China, and how to include these new provisions in the relevant agreements.